biotech

BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Prevail Therapeutics shares absolutely exploded on Tuesday morning after it was announced that the company would be acquired by Eli Lilly.
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
CureVac advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study. As a result, investors cheered on this news and sent shares higher.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Curis shares are on the run again. This time it’s due to a secondary offering.
Curis has announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
After scPhamaceuticals announced that it had received a Complete Response Letter from the FDA, its shares were absolutely crushed on Monday.
Sutro Biopharma made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Moderna shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.